Lilly targets quarterly deals worth up to $5bn to boost R&D

Eli Lilly is targeting a deal worth between $1 billion to $5 billion every quarter in 2020 as it seeks to build its R&D pipeline, its chief financial officer has said.

Novo's Ozempic gains MACE risk reduction label in US

Novo Nordisk’s Ozempic (semaglutide) weekly GLP-1 injection has gained a new US indication after the FDA agreed a label extension to cover reducing the risk of cardiac events in adults with

Lilly swoops on Dermira to claim Dupixent rival

Lilly claims another victory in Alimta patent defence

Lilly doubles down on Dexcom tech for connected insulin devi...

Boehringer, Lilly start acute heart failure trial with Jardi...